RBC raised price target on Alnylam Pharmaceuticals on July 7, 2025.
2 reports, 0 independent
Updated Jul 7
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
RBC raised price target on Alnylam Pharmaceuticals on July 7, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- RBC raised price target on Alnylam Pharmaceuticals.
- RBC raised price target on Acadia Pharmaceuticals.
Keep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
Royal Bank of Canada
financial institution in Canada
-
Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.
Nothing else this week.
Related events
- RBC raised its target price for Howmet Aerospace, while Citigroup reiterated a 'buy' rating on the shares.
- Royal Bank of Canada raised its target price on USA Compression Partners, LP on June 7, 2026.
- RBC raised price target for AutoCanada stock on August 18, 2026.
- Royal Bank of Canada raised its price target on Webster Financial on July 2, 2025.
- RBC raised the price target on Range Resources in July 2025.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet